## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL	
OMB Number:	3235-0	287
Estimated average	burden	
nours per response	e	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																	
1. Name and Address of Reporting Person* Newell Joe				2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]								5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner						
(Last) (First) (Middle) C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900				3. Date of Earliest Transaction (Month/Day/Year) 11/17/2020									X_Office	r (give title belo Chief	Operations	Other (specify l Officer	pelow)		
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line)  X_Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City		(State)		Zip)			Ta	able I	- Non	-De	rivative S	Securit	ties A	cquir	ed, Dispo	sed of, or I	Beneficially	Owned	
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		Execu any	Deemed ution Date, if		(Instr. 8)		tion	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		D)	Beneficially Owned Reported Transaction		Following (s)	Ownership Form:	Beneficial		
					(Mont	h/Day/Y	ear)	Co	de	V	Amount	(A) or (D)	Pri		or (I)		or Indirect	Ownership (Instr. 4)	
Common	Stock		11/17/2	2020				SC	<u>1)</u>		1,648	D	\$ 19.7 (2)	774	116,555	5		D	
Reminder:	Report on a s	separate line f		Table II - l	Deriva	ative Sec	curit	ies Ac	equire	Pers con the	sons whatained in form dis	no responded the splays	form a cu Benefi	are irrent	not requ tly valid		ormation spond unle rol numbe	ss	1474 (9-02)
1. Title of	2	3. Transaction	on 3A	. Deemed	<i>e.g.</i> , p	outs, call	s, wa	arrant 5.	ts, op		s, conver				le and	8 Price of	9. Number	of 10.	11. Natur
	Conversion or Exercise Price of Derivative Security	Date	ay/Year) (Month/Day			Transac Code	)			and Expiration Date (Month/Day/Year)  AU Se		Amou Under Secur (Instr.	unt of rlying		Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivati Security Direct ( or Indire	of Indirect Beneficia Ownershi (Instr. 4)		
					Code	Code	V	(A)	(D)	Dat Exe	e ercisable	Expira Date	tion ,		Amount or Number of Shares				

#### **Reporting Owners**

	Relationships									
Reporting Owner Name / Address	Director	10% Owner	Officer	Other						
Newell Joe C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO, CA 94080			Chief Operations Officer							

### **Signatures**

/s/ David Tucker, Attorney-in-Fact for Joe Newell	11/18/2020
Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units.
- (2) The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 17, 2020 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.